E-LIB Suche - Ergebnisse für: Sellam, Gila

1

Safety and efficacy of atezolizumab with rituximab and CHOP..:

Younes, Anas ; Burke, John M. ; Cheson, Bruce D....
Blood Advances. 7 (2023) 8 - p. 1488-1495 , 2023

Link: https://doi.org/10.1182/..

2

A comparison of the prognostic performance of the Lugano 20..:

Kostakoglu, Lale ; Martelli, Maurizio ; Sehn, Laurie H....
eJHaem. 4 (2023) 4 - p. 1042-1051 , 2023

Link: https://doi.org/10.1002/..

3

Safety and efficacy of atezolizumab with obinutuzumab and b..:

Younes, Anas ; Burke, John M. ; Diefenbach, Catherine...
Blood Advances. 6 (2022) 20 - p. 5659-5667 , 2022

Link: https://doi.org/10.1182/..

4

Baseline Total Metabolic Tumor Volume is Prognostic for Ref..:

Ruiz, Irene Canales ; Martelli, Maurizio ; Sehn, Laurie H....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) 8 - p. e804-e814 , 2022

Link: https://doi.org/10.1016/..

5

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refr..:

Topp, Max S. ; Eradat, Herbert ; Florschütz, Axel...
Journal of Cancer Research and Clinical Oncology. 149 (2022) 2 - p. 811-817 , 2022

Link: https://doi.org/10.1007/..

6

End-of-treatment PET/CT predicts PFS and OS in DLBCL after ..:

Kostakoglu, Lale ; Martelli, Maurizio ; Sehn, Laurie H....
Blood Advances. 5 (2021) 5 - p. 1283-1290 , 2021

Link: https://doi.org/10.1182/..

7

ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unf..:

Olszewski, Adam ; Avigdor, Abraham ; Babu, Sunil...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S395-S396 , 2021

Link: https://doi.org/10.1016/..

8

Poster: ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Eld..:

Olszewski, Adam ; Avigdor, Abraham ; Babu, Sunil...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S239 , 2021

Link: https://doi.org/10.1016/..

9

Total metabolic tumor volume as a survival predictor for pa..:

Kostakoglu, Lale ; Mattiello, Federico ; Martelli, Maurizio...
Haematologica. 107 (2021) 7 - p. 1633-1642 , 2021

Link: https://doi.org/10.3324/..

10

A randomized, open-label, Phase III study of obinutuzumab o..:

Sehn, Laurie H. ; Martelli, Maurizio ; Trněný, Marek...
Journal of Hematology & Oncology. 13 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..

11

Impact of bone marrow biopsy on response assessment in immu..:

Martin, Peter ; Sellam, Gila ; Sahin, Deniz...
Blood Advances. 4 (2020) 8 - p. 1589-1593 , 2020

Link: https://doi.org/10.1182/..

12

Physiological parameters after nonpharmacological analgesia..:

Gerull, Roland ; Cignacco, Eva ; Stoffel, Liliane..
Acta Paediatrica. 102 (2013) 8 - p. , 2013

Link: https://doi.org/10.1111/..

13

Safety and efficacy of atezolizumab with rituximab and CHOP..:

Younes, Anas ; Burke, John M ; Cheson, Bruce D...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125909/. , 2022

Link: http://www.ncbi.nlm.nih...

14

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refr..:

Topp, Max S ; Eradat, Herbert ; Florschütz, Axel...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931830/. , 2022

Link: http://www.ncbi.nlm.nih...

15

End-of-treatment PET/CT predicts PFS and OS in DLBCL after ..:

Kostakoglu, Lale ; Martelli, Maurizio ; Sehn, Laurie H...
Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2020002690. , 2021

Link: http://hdl.handle.net/24..